The availability, cost and affordability of essential medicines for asthma and COPD in LMIC: a systematic review, Lancet Global Health 2022

This systematic review, commissioned by WHO, explored the availability, cost and affordability of essential medicines for asthma and COPD in LMICs in published literature between 2010-2022. Inhaled medicines were largely unavailable and unaffordable – this was particularly true for inhalers containing corticosteroids.